Dopamine Synthesis Capacity Before Onset of Psychosis: A Prospective [18F]-DOPA PET Imaging Study
Publication: American Journal of Psychiatry
Abstract
Objective:
While there is robust evidence of elevated dopamine synthesis capacity once a psychotic disorder has developed, little is known about whether it is altered prior to the first episode of frank illness. The authors addressed this issue by measuring dopamine synthesis capacity in individuals at ultra-high risk of psychosis and then following them to determine their clinical outcome.
Method:
This prospective study included 30 patients who met standard criteria for being at ultra-high risk of psychosis and 29 healthy volunteers. Participants were scanned using [18F]6-fluoro-l-dopa positron emission tomography. The ultra-high-risk patients were scanned at presentation and followed up for at least 3 years to determine their clinical outcome. Six patients had comorbid schizotypal personality disorder and were excluded from the analysis (data are provided for comparison). Of the remaining patients, nine developed a psychotic disorder (psychotic transition group) and 15 did not (nontransition group).
Results:
There was a significant effect of group on striatal dopamine synthesis capacity. The psychotic transition group had greater dopamine synthesis capacity in the striatum (effect size=1.18) and its associative subdivision (effect size=1.24) than did the healthy comparison subjects and showed a positive correlation between dopamine synthesis capacity and symptom severity. Dopamine synthesis capacity was also significantly greater in the psychotic transition group than in the nontransition group.
Conclusions:
These findings provide evidence that the onset of frank psychosis is preceded by presynaptic dopaminergic dysfunction. Further research is needed to determine the specificity of elevated dopamine synthesis capacity to particular psychotic disorders.
A substantial body of evidence implicates dopaminergic dysfunction in the etiology of psychotic disorders (1–4). In particular, converging in vivo evidence from positron emission tomography (PET) and other molecular imaging studies indicates that psychotic disorders are associated with dysregulated presynaptic striatal dopaminergic function (for reviews, see references 1, 5, 6). It has thus been proposed that striatal hyperdopaminergia underlies the onset of psychosis, preceding illness onset and increasing further to lead to the development of frank psychosis (4, 7).
The onset of psychotic disorders is typically preceded by a prodromal phase, characterized by functional decline and attenuated psychotic symptoms—perceptual disturbances and paranoid ideas that are less severe than in frank psychosis (8, 9). Structured assessments and operationalized criteria have been developed for identifying the clinical features (termed an “at-risk mental state”) that are associated with an ultra-high risk of developing psychosis. Patients who meet these criteria are said to be at ultra-high risk for psychosis, as about one-third will develop a psychotic illness within 2 years (9, 10).
We previously reported that dopamine synthesis capacity is higher on average in ultra-high-risk patients than in healthy comparison subjects (11). However, at the time of that study, the clinical outcome of the study participants was yet to be determined. Because only a proportion of those at ultra-high risk will subsequently develop a psychotic disorder, the relationship between dopamine dysfunction and the subsequent onset of illness is still unclear. In the present study, we tested the hypothesis that dopamine synthesis capacity would be elevated in the group of ultra-high-risk patients who went on to develop psychosis relative to the healthy comparison group. A related prediction was that within this group, the severity of presenting symptoms would be directly related to dopamine synthesis capacity. Because schizotypal personality disorder is independently associated with presynaptic dopaminergic dysfunction and psychotic-like symptoms (12–15), we excluded ultra-high-risk patients with schizotypal personality disorder from the main analysis, but we present their data for comparison. As altered dopamine synthesis capacity may be localized to the associative subdivision of the striatum in psychotic disorders (11), we examined striatal subdivisions in addition to the striatum as a whole.
Method
Participants
The study was approved by the participating hospitals' research ethics committees, and all participants gave written informed consent. Patients who met the Comprehensive Assessment of At-Risk Mental States (8) criteria for ultra-high risk of psychosis on the basis of attenuated psychotic symptoms (N=30; mean age=25.0 years [SD=4.1]; 17 of them [57%] male) were studied using [18F]6-fluoro-l-dopa ([18F]DOPA) PET at clinical presentation. We previously reported baseline data in a subgroup (N=24) of this ultra-high-risk sample (11), but at that early stage their subsequent clinical outcome was unknown. The present study includes follow-up data on all ultra-high-risk patients included in our original baseline study (11) plus follow-up data on six additional ultra-high-risk patients recruited after that study was published. A minimum of 3 years of follow-up was used, as the great majority of transitions to psychosis in ultra-high-risk patients occur within this interval (9, 10). Six of the ultra-high-risk patients met DSM-IV criteria for comorbid schizotypal personality disorder and were excluded from the analysis because this disorder has been independently associated with elevated striatal dopamine release (13). However, we present their data separately for comparison. The analysis thus includes the remaining 24 ultra-high-risk patients (15 of them [63%] male) and the matched healthy comparison subjects. All of these participants were antipsychotic naive.
Healthy comparison subjects (N=29; 20 of them [69%] male) were recruited contemporaneously from the same geographical area and sociodemographic background by local advertisement and by approaching the social contacts of ultra-high-risk patients (after first receiving written permission to do so). They were matched to the ultra-high-risk group on the basis of age (within 5 years). Parental socioeconomic status and ethnicity were determined using U.K. standard criteria (the five-class categorization; see www.ons.gov.uk/about-statistics/classifications/current/soc2010/soc2010-volume-3-ns-sec--rebased-on-soc2010--user-manual/index.html). Exclusion criteria for all participants were a history of a neurological or medical disorder (other than past minor self-limiting illnesses) or head injury; illicit drug or alcohol abuse or dependence; pregnancy; or contraindication to scanning. All participants were instructed to fast and to abstain from psychoactive substances, including caffeine, tobacco, and alcohol, for at least 12 hours before scanning. All participants received a urine drug screen 1 hour before scanning and clinical assessments to confirm that they had not recently taken any illicit substances. Additional exclusion criteria for comparison subjects were a family history of a psychotic disorder or a personal history of any axis I or II psychiatric disorder, assessed using the Structured Clinical Interview for DSM-IV (SCID; 16).
Clinical outcomes at follow-up were determined using the SCID. This assessment was conducted by an experienced psychiatrist who was independent of the study, was blind to the imaging data, and was trained in the use of the interview. All patients recruited into the study completed follow-up. Nine of the ultra-high-risk patients (38%) developed a psychotic disorder (the psychotic transition group) within the follow-up period. These disorders included schizophrenia (N=7), schizophreniform disorder (N=1), and bipolar I disorder with a psychotic manic episode (N=1). The remaining ultra-high-risk patients (N=15) have not developed a psychotic disorder (the nontransition group). None of the patients in the schizotypal personality disorder group have developed a psychotic disorder to date.
Clinical Measures
The following instruments were used to assess subjects at the time of the scan: the Comprehensive Assessment of At-Risk Mental States (8), the Positive and Negative Syndrome Scale (PANSS) (17), the Global Assessment of Functioning scale (GAF), and a structured questionnaire for assessing exposure to cigarettes and alcohol (adapted from the Cannabis Experiences Questionnaire [18]; available on request).
PET Scanning
Participants underwent [18F]DOPA PET imaging using an ECAT/EXACT3D PET scanner (Siemens/CTI, Knoxville, Tenn.). Participants received 150 mg of carbidopa and 400 mg of entacapone orally 1 hour before scanning to reduce the formation of radiolabeled metabolites. Participants were positioned with the orbitomeatal line parallel to the transaxial plane of the tomograph, and head position was marked and monitored throughout the scan via laser crosshairs and a camera. The 95-minute emission scan was preceded by a short transmission scan using a 150-MBq cesium-137 rotating point source to correct for attenuation and scatter. Thirty seconds after the start of the emission scan, a bolus intravenous injection of 150 MBq of [18F]DOPA was administered. Structural MRI was performed to exclude intracranial abnormalities.
Image Analysis
Region-of-interest analysis.
The region-of-interest analysis was carried out blind to group status (by O.D.H.) and comprised the whole striatum and the limbic, associative, and sensorimotor subdivisions of the striatum (illustrated in Figure S1 in the data supplement that accompanies the online edition of this article). The whole striatum and its subdivisions were defined using previously described criteria and combining the left and right sides (11, 19). The striatal subdivisions reflect the topographical arrangement of corticostriatal projections and the functional organization of the striatum (19, 20) (see the online data supplement).
Regions of interest were automatically placed on individual [18F]DOPA PET dynamic images without observer bias by using statistical parametric mapping software (SPM5; Wellcome Department of Cognitive Neurology, London) to normalize the region-of-interest map to each individual PET space (using the PET summation image). A Patlak graphical analysis was used to calculate influx constants (kicer values, where ki indicates it is the influx constant and cer denotes the reference region used). kicer values were determined for the regions of interest relative to uptake in the reference region (21). The reference region was the cerebellum, as defined using the HamNet probabilistic brain atlas (22). Striatal [18F]DOPA kicer values (denoted as Ki in some previous publications [11]) reflect the presynaptic synthesis and storage of striatal dopamine for release, respond to experimental manipulation of brain dopaminergic systems, and correlate with the striatal release of dopamine (11, 23).
Voxel-based analysis.
The region-of-interest analysis was complemented by an independent voxel-based analysis. Voxel-based kicer parametric images of the brain were constructed from movement-corrected images using a wavelet-based Patlak approach that provides a higher signal-to-noise ratio than the original graphical procedure (24). The parametric image for each participant was then normalized into standard space using the participant's PET summation image and the [18F]DOPA template. Statistical parametric mapping was conducted using SPM5 and a striatal mask defined according to previously described criteria (19) to compare groups. Results are presented corrected for multiple comparisons using random field theory as applied in SPM5 (p<0.05, corrected at the family-wise error rate).
Statistical Analysis
The data were normally distributed as assessed using the Kolmogorov-Smirnov test apart from the substance use data. After confirming homogeneity of variance with Levene's test, analysis of variance was used to determine whether there was an effect of group (psychotic transition, nontransition, and healthy comparison groups) on striatal kicer value and demographic and clinical variables for parametric variables, and the Kruskal-Wallis test was used for nonparametric variables. Where there were significant group effects, independent t tests using Bonferroni correction for multiple comparisons (four striatal regions across three groups) were used to determine whether mean kicer values were significantly elevated in the psychotic transition group relative to the healthy comparison group in line with the main hypothesis, and to determine whether there were significant differences in mean kicer values between the nontransition and comparison groups and between the psychotic transition and nontransition groups. The relationship between kicer values and symptom scores was explored using Pearson's correlation coefficient, and the influence of individual data points was assessed using Cook's distance-centered leverage plots. Mean kicer values in the schizotypal personality disorder group were compared with those in the psychotic transition and nontransition groups using independent t tests, but this analysis should be considered exploratory as we had no a priori hypotheses for this comparison. A two-tailed significance threshold of 0.05 was used throughout.
Results
Demographic and Clinical Characteristics
There was no significant effect of group on mean age, parental socioeconomic status, cigarette or alcohol use, or radioactivity administered (psychotic transition group, mean=148.2 MBq [SD=5.2]; nontransition group, mean=148.8 MBq [SD=3.4]; healthy comparison group, mean=142.9 MBq [SD=14.0]). In ethnic composition, the psychotic transition group was 56% white, 33% black, and 11% other; the nontransition group was 53% white, 27% black, and 20% other; and the healthy comparison group was 52% white, 41% black, and 7% other. There was no significant difference in the clinical characteristics between the psychotic transition and nontransition groups at the time of imaging (Table 1).
| Healthy Comparison Group (N=29) | Psychotic Transition Group (N=9) | Nontransition Group (N=15) | ||||
|---|---|---|---|---|---|---|
| Characteristic | Mean | SD | Mean | SD | Mean | SD |
| Age (years) | 25.6 | 4.0 | 24.9 | 3.1 | 23.8 | 3.7 |
| Parental socioeconomic statusb | 3.0 | 0.9 | 2.9 | 0.9 | 3.0 | 0.9 |
| Cigarettes/day | 2.8 | 5.2 | 5.2 | 5.8 | 5.2 | 5.5 |
| Alcohol (units/week) | 10.0 | 10.5 | 6.5 | 6.8 | 4.8 | 4.6 |
| Comprehensive Assessment of At-Risk Mental Statec | ||||||
| Total score | 40.3 | 22.1 | 35.1 | 20.3 | ||
| Positive score | 8.1 | 3.0 | 7.4 | 4.1 | ||
| Positive and Negative Syndrome Scale | ||||||
| Total score | 50.2 | 21.9 | 44.5 | 12.7 | ||
| Positive score | 13.8 | 5.7 | 11.4 | 3.3 | ||
| Global Assessment of Functioning scale score | 56.0 | 11.3 | 59.6 | 14.2 | ||
a
Patients in the psychotic transition group were those who subsequently developed a psychotic disorder, and those in the nontransition group were those who did not. There were no significant differences between groups on any characteristic.
b
Higher scores indicate lower socioeconomic status (possible scores range from 1 to 5, where 1=highest and 5=lowest).
c
Higher scores indicate more severe high-risk symptoms.
Striatal Dopamine Synthesis Capacity
The region-of-interest analysis revealed that there was a significant effect of group on mean kicer value in the whole striatum (Figure 1; F=5.8, df=2, 50, p=0.006) and in its associative subdivision (F=5.8, df=2, 50, p=0.006), but not in the limbic or sensorimotor subdivisions. The group effect remained significant after excluding the one patient in the psychotic transition group who had developed a non-schizophreniform psychosis (whole striatum: F=5.1, df=2, 49, p=0.01; associative striatum: F=4.8, df=2, 49, p=0.013).
FIGURE 1. Mean Dopamine Synthesis Capacity in Patients at Ultra-High Risk of Psychosis and Healthy Comparison Subjectsa
a Dopamine synthesis capacity (kicer values) for the whole striatum in patients who developed psychosis (the psychotic transition group, N=9), patients who did not develop psychosis (the nontransition group, N=15), and the healthy comparison group (N=29). There were significant differences between psychotic transition and healthy comparison groups (p=0.004, corrected for multiple comparisons) and between the psychotic transition and nontransition groups (p=0.015, corrected for multiple comparisons). Error bars indicate standard deviation.
Comparison Between the Psychotic Transition and Healthy Comparison Groups
The comparison between the psychotic transition and healthy comparison groups showed that after adjustment for multiple comparisons, mean kicer values were significantly elevated in the psychotic transition group in the whole striatum (psychotic transition group, mean=0.0153/min [SD=0.0012]; comparison group, mean=0.0140/min [SD=0.0010]; p=0.004, corrected) and in its associative subdivision (psychotic transition group, mean=0.0149/min [SD=0.0011]; comparison group, mean=0.0136/min [SD=0.0010]; p=0.015, corrected). The effect size (Cohen's d) of the elevation in kicer was 1.18 in the whole striatum and 1.24 in the associative striatum. There was no significant difference in the limbic (psychotic transition group, mean=0.0153/min [SD=0.0013]; comparison group, mean=0.0140/min [0.0019]; p=0.2) or sensorimotor (psychotic transition group, mean=0.0164/min [SD=0.0015]; comparison group, mean=0.0152/min [SD=0.0015]; p=0.095) striatal subdivisions. The voxel-based analysis also identified a greater kicer in the psychotic transition group relative to the comparison group in a voxel cluster with its focus in the left head of the caudate, which lies within the associative subdivision (Figure 2). This difference was significant at p<0.05, corrected for multiple comparisons using the family-wise error rate, and it remained significant after excluding the psychotic transition patient with a non-schizophreniform psychosis. The healthy comparison group > psychotic transition group contrast revealed no significant difference, even at an uncorrected statistical threshold (p<0.05).
FIGURE 2. Increased Striatal Dopamine Synthesis Capacity in Patients With Prodromal Psychotic Symptoms Who Later Developed a Psychotic Disorder, Relative to Healthy Comparison Subjectsa
a The images show increased dopamine synthesis capacity, relative to healthy comparison subjects (N=29), in patients who were scanned when they presented with prodromal symptoms and subsequently developed a psychotic disorder (psychotic transition group, N=9). The most significant increase was in the head of the left caudate nucleus (p=0.007, corrected at the family-wise error rate).
Comparison Between the Psychotic Transition and Nontransition Groups
After adjustment for multiple comparisons, the kicer value was significantly elevated in the psychotic transition compared to the nontransition group in the whole striatum (Figure 1; nontransition group, mean=0.0142/min [SD=0.0011], p=0.036) and its associative subdivision (nontransition group, mean=0.0136/min [SD=0.0012], p=0.015), but not in the limbic (nontransition group, mean=0.0149/min [SD=0.0015], p>0.990), or sensorimotor (nontransition group, mean=0.0153/min [SD=0.0013], p=0.222) striatal subdivisions. The voxel-based analysis also identified a greater striatal kicer in the psychotic transition group than in the nontransition group, with a peak in the caudate (Figure 3; p=0.036, corrected at the family-wise error rate). The contrast of the nontransition group > psychotic transition group showed no significant differences, even at an uncorrected statistical threshold (p<0.05).
FIGURE 3. Increased Striatal Dopamine Synthesis Capacity in Patients With Prodromal Psychotic Symptoms Who Later Developed a Psychotic Disorder, Relative to Those Who Did Nota
a Increased dopamine synthesis capacity in patients who were scanned when they presented with prodromal symptoms and subsequently developed a psychotic disorder (psychotic transition group, N=9) relative to patients who presented with similar symptoms but did not develop a psychotic disorder (nontransition group, N=15). The most significant increase was in the left caudate (p=0.036, corrected at the family-wise error rate).
Comparison Between the Nontransition and Healthy Comparison Groups
The region-of-interest analysis indicated that there was no significant difference in mean kicer value in the nontransition group relative to the healthy comparison group in the whole striatum or its subdivisions, and there were no significant differences in the corresponding voxel-based analysis for the contrast of nontransition group > comparison group, even at an uncorrected threshold (p<0.05).
The Relationship Between Striatal Dopamine Synthesis Capacity and Symptoms
Within the psychotic transition group, there was a significant positive relationship between whole striatal kicer values and total score on both the Comprehensive Assessment of At-Risk Mental States (Figure 4; r=0.67, p=0.049) and the PANSS rating scales (r=0.71, p=0.032). These findings were not driven by outlying or high-influence data points, as assessed using Cook's distance-centered leverage plots. These correlations were not evident in the nontransition group.
FIGURE 4. Association of Prodromal Symptom Severity and Striatal Dopamine Synthesis Capacity at Presentation in Patients Who Subsequently Developed Psychosisa
a Prodromal symptom severity is rated on the Comprehensive Assessment of At-Risk Mental States total score. Greater severity of prodromal symptoms is associated with greater dopamine synthesis capacity in the whole striatum (kicer value/min) at presentation in patients who subsequently developed psychosis (N=9, r=0.67, p=0.049).
Striatal Dopamine Synthesis Capacity in the Schizotypal Personality Disorder Group
There was no significant difference in the kicer values between the schizotypal personality disorder and psychotic transition groups (the kicer values for the schizotypal personality disorder group and the statistical comparisons are presented in the online data supplement). However, kicer values were significantly elevated in the schizotypal personality disorder group relative to the healthy comparison group in the whole striatum (p=0.006) and its associative (p=0.003) and sensorimotor (p=0.047) but not limbic subdivisions, and relative to the nontransition group in the associative (p=0.023) subdivision, but this difference fell short of statistical significance in the whole striatum (p=0.053) and was not significant in the sensorimotor or limbic subdivisions.
Discussion
We found that dopamine synthesis capacity was elevated with a large effect size (>1) in the patients who presented with prodromal signs of psychosis and went on to a first episode of a psychotic disorder. This elevation was evident relative to healthy comparison subjects and to patients who presented with similar clinical features but did not go on to develop psychosis. In the psychotic transition group, there was a direct relationship between the magnitude of dopaminergic dysfunction and the severity of prodromal symptoms at presentation. Dopamine synthesis capacity in the ultra-high-risk patients who did not subsequently develop psychosis was not significantly different from that in healthy comparison subjects and was not correlated with symptom severity at presentation.
These findings support the dopamine hypothesis (4, 7) by providing the first evidence, to our knowledge, that dopaminergic dysfunction predates the onset of frank psychotic illness in people with symptoms that are truly prodromal to a psychotic disorder, and extend our finding of a longitudinal increase in dopamine synthesis capacity in this group (25). These findings do not preclude the involvement of other neurotransmitter systems that may act upstream to alter dopaminergic function (26, 27). For example, animal studies show that cortical damage can alter striatal dopaminergic function (28, 29), and human neuroimaging data indicate that cortical dysfunction is related to striatal dopaminergic function in both ultra-high-risk patients (30) and patients with schizophrenia (31, 32). Furthermore, we recently found an altered relationship between striatal dopaminergic and cortical glutamatergic indices in psychotic transition patients (33), suggesting that both may be involved in the development of psychosis.
Findings in the Schizotypal Personality Disorder Group
The finding that dopamine synthesis capacity was elevated in the schizotypal personality disorder group relative to the healthy comparison group is consistent with evidence that individuals with schizotypal personality disorder show elevated dopamine release, at a level similar to that in patients with remitted schizophrenia and intermediate between levels in acute schizophrenia and in healthy comparison subjects (13). Because schizotypal personality disorder is independently associated with a greater lifetime risk of schizophrenia relative to the general population (14), the patients in the schizotypal personality disorder group probably continue to have an elevated risk of developing schizophrenia despite not having developed it during the follow-up period. Our data, along with previous findings in schizotypal personality disorder, thus suggest that dopaminergic dysfunction may be related to vulnerability to schizophrenia spectrum disorders, rather than to frank psychosis per se.
However, because a proportion of ultra-high-risk patients in any given sample are likely also to have comorbid schizotypal personality disorder (8), the lack of differences between the psychotic transition and schizotypal personality disorder groups limits the utility of this PET measure as a marker for impending psychosis, although greater sensitivity may be achieved using novel image analytic approaches (34).
Methodological Considerations
A critical consideration in all longitudinal studies in ultra-high-risk samples is that some subjects who have not developed psychosis might still do so after the end of the follow-up period. However, follow-up of ultra-high-risk patients indicates that the great majority of transitions occur within the first 24 months, after which the transition rate sharply declines (9, 10), although occasional transitions may still occur several years after presentation. In the present study, all the patients were followed up for at least 36 months. The development of psychosis has also been associated with reductions in gray matter volume, but in the cerebral cortex rather than in the striatum (35). Moreover, the PET normalization procedure we employed is accurate even when there is structural change (36), and striatal volume loss would, if anything, reduce rather than increase kicer values (37). It thus seems unlikely that our neurochemical findings were secondary to structural alterations in the striata of the psychotic transition group. However, given the evidence of altered corticostriatal interactions in ultra-high-risk patients, future work should investigate the relationship between cortical changes and striatal dopaminergic function. While we could not detect a significant difference in dopamine synthesis capacity between the nontransition group and the healthy comparison group, we cannot exclude the possibility that this reflected a lack of statistical power. Studies using larger samples are needed to clarify whether dopamine synthesis capacity in the nontransition group is intermediate between that in psychotic transition patients and healthy volunteers.
Specificity of the Findings
Our key clinical outcome measure was the development of a first episode of a psychotic disorder, and thus the findings support a link between dopamine dysfunction and psychosis in general rather than as a manifestation of a particular psychotic disorder. Nevertheless, all but one of the patients who developed psychosis met diagnostic criteria for a schizophreniform disorder, and exclusion of the one patient who met criteria for bipolar disorder did not alter the results. It is possible that the findings may vary with type of psychotic disorder, and this issue may be addressed in future studies.
Our finding that the dopaminergic abnormality in the psychotic transition group was localized to the associative striatum extends previous findings in schizophrenia that elevations in dopamine synthesis capacity (11) and synaptic dopamine levels (38) are localized to the associative striatum, by indicating for the first time that this is also the case in the prodrome that precedes the first episode of psychosis. The associative striatum is functionally linked to the dorsolateral prefrontal cortex (see Figure S1 in the online data supplement), a cortical area that has been shown to be the site of functional impairments in ultra-high-risk patients (39). Our finding in the associative striatum thus suggests that frontal-striatal interactions may be important in the development of psychosis. While [18F]DOPA PET measurements in the striatum show high reliability (40), reliability is lower in smaller structures. However, the voxel-based analysis localized the peak difference to the left head of the caudate, which is within the associative striatum, and thus supports the associative localization of dopaminergic abnormalities and suggests that there may be a lateralization effect that warrants further investigation. Finally, our findings are unlikely to be an effect of antipsychotic medication, as all the ultra-high-risk patients were antipsychotic naive.
Acknowledgments
The authors are grateful to the volunteers and staff of the OASIS (Outreach and Support in South London) and LEO (Lambeth Early Onset) teams (South London and Maudsley NHS Foundation Trust) and of GE Imanet.
Footnote
Received Jan. 28, 2011; revision received April 19, 2011; accepted May 26, 2011.
Supplementary Material
File (appi.ajp.2011.11010160.ds001.pdf)
- View/Download
- 31.33 KB
References
1.
Abi-Dargham A: Do we still believe in the dopamine hypothesis? new data bring new evidence. Int J Neuropsychopharmacol 2004; 7(suppl 1):S1–S5
2.
Heinz A, Schlagenhauf F: Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 2010; 36:472–485
3.
Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK: Molecular imaging studies of the striatal dopa-minergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 2007; 51:S13–S18
4.
Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474–1486
5.
Laruelle M, Abi-Dargham A: Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999; 13:358–371
6.
Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S: Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009; 15:2550–2559
7.
Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III: the final common pathway. Schizophr Bull 2009; 35:549–562
8.
Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J: Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust NZ J Psychiatry 2005; 39:964–971
9.
Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R: Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65:28–37
10.
Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, Phillips LJ, Bechdolf A, Buckby J, McGorry PD: Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res 2008; 105:10–17
11.
Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM: Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66:13–20
12.
Siever LJ, Amin F, Coccaro EF, Bernstein D, Kavoussi RJ, Kalus O, Horvath TB, Warne P, Davidson M, Davis KL: Plasma homovanillic acid in schizotypal personality disorder. Am J Psychiatry 1991; 148:1246–1248
13.
Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O'Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ: Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 2004; 55:1001–1006
14.
Siever LJ, Davis KL: The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 2004; 161:398–413
15.
Siever LJ, Amin F, Coccaro EF, Trestman R, Silverman J, Horvath TB, Mahon TR, Knott P, Altstiel L, Davidson M, Davis KL: CSF homovanillic acid in schizotypal personality disorder. Am J Psychiatry 1993; 150:149–151
16.
Spitzer RL, Williams JBW, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV (SCID). Washington, DC, American Psychiatric Press, 1994
17.
Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–276
18.
Barkus EJ, Stirling J, Hopkins RS, Lewis S: Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 2006; 39:175–178
19.
Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography, part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23:285–300
20.
Haber SN: The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 2003; 26:317–330
21.
Patlak CS, Blasberg RG, Fenstermacher JD: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3:1–7
22.
Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS: Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003; 19:224–247
23.
Kumakura Y, Cumming P: PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist 2009; 15:635–650
24.
Turkheimer FE, Aston JA, Asselin MC, Hinz R: Multi-resolution Bayesian regression in PET dynamic studies using wavelets. Neuroimage 2006; 32:111–121
25.
Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray R, McGuire P: Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry (Epub ahead of print, March 1, 2011)
26.
Heinz A, Romero B, Gallinat J, Juckel G, Weinberger DR: Molecular brain imaging and the neurobiology and genetics of schizophrenia. Pharmacopsychiatry 2003; 36(suppl 3):S152–S157
27.
Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA: Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31:234–242
28.
Chrapusta SJ, Egan MF, Wyatt RJ, Weinberger DR, Lipska BK: Neonatal ventral hippocampal damage modifies serum corticosterone and dopamine release responses to acute footshock in adult Sprague-Dawley rats. Synapse 2003; 47:270–277
29.
Pycock CJ, Kerwin RW, Carter CJ: Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980; 286:74–76
30.
Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P: Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 2011; 16:67–75
31.
Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF: Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002; 5:267–271
32.
Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, Frank JA, Pickar D, Weinberger DR: The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000; 22:125–132
33.
Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, O'Gorman RL, McLean MA, Barker GJ, McGuire P: Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry 2010; 68:599–602
34.
Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, Grasby PM: Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res 2008; 106:148–155
35.
Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ, van Erp TG, Thompson PM, Toga AW, Cannon TD, Pantelis C: Progressive brain structural changes mapped as psychosis develops in “at risk” individuals. Schizophr Res 2009; 108:85–92
36.
Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, Dagher A, Jenkins IH, Friston KJ, Brooks DJ: Frontal, midbrain, and striatal dopaminergic function in early and advanced Parkinson's disease: a 3D [(18)F]dopa-PET study. Brain 1999; 122:1637–1650
37.
Binkofski F, Reetz K, Gaser C, Hilker R, Hagenah J, Hedrich K, van Eimeren T, Thiel A, Büchel C, Pramstaller PP, Siebner HR, Klein C: Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology 2007; 69:842–850
38.
Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M: Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67:231–239
39.
Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Grasby PM, McGuire PK: Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 2010; 67:683–691
40.
Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD: The test-retest reliability of 18F-dopa PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 2010; 50:524–531
Information & Authors
Information
Published In
History
Received: 28 January 2011
Revision received: 19 April 2011
Accepted: 26 May 2011
Published online: 1 December 2011
Published in print: December 2011
Authors
Funding Information
Dr. Murray has received speaking honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen, Eli Lilly, and Novartis. The other authors report no financial relationships with commercial interests.Supported by grant U.1200.04.007.00001.01 from the Medical Research Council, U.K., and the National Institute for Health Research Biomedical Research Centre for Mental Health.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).